United States
    Michael Celano

    Michael Celano

    Chairman of the Board, OraSure Technologies, Inc.
    Chief Financial Officer, Larimar Therapeutics, Inc.

    Michael Celano became a member of the Board in 2006 and has served as the Company’s Chairman of the Board since April 2018. Mr. Celano has served as Chief Financial Officer of Larimar Therapeutics, Inc., since May 2020. From 2016 to 2019, Mr. Celano held the positions of Chief Financial Officer and then Chief Operating Officer of Recro Pharma, Inc. From 2013 to 2015, Mr. Celano served as Chief Financial Officer of DrugScan, Inc. Prior to that, Mr. Celano served as the Chief Financial Officer of Kensey Nash Corporation from 2009 to 2012. Prior to Kensey Nash, Mr. Celano also served as Chief Financial Officer for BioRexis Pharmaceutical Corporation. Mr. Celano also served as a partner with KPMG LLP, where he was co-leader of its National Life Science Practice. Mr. Celano also was co-leader of the Life Science Practice for Arthur Andersen before he joined KPMG. Mr. Celano previously served on the Board of Directors of Performance Health from 2015 to 2016. Throughout his career Mr. Celano has provided consulting and advisory services to healthcare companies. Mr. Celano holds a B.S. in Accounting from St. Joseph’s University.

    Mara Aspinall

    Mara G. Aspinall

    President and Chief Executive Officer, Health Catalysts Group

    Mara G. Aspinall became a member of the Board in June 2017 and serves on the Audit Committee and the Compensation Committee. Since 2014, she has served as the President and Chief Executive Officer of Health Catalysts Group, a consulting firm that focuses on growth of early stage life science and technology companies. Ms. Aspinall is also Managing Director of BlueStone Venture Partners, a venture capital firm dedicated to investing in life sciences and healthcare related companies. Prior to these positions, Ms. Aspinall served as President and CEO, Global Head of Roche Tissue Diagnostics/Ventana Medical Systems, a division of The Roche Group that provides tissue-based cancer diagnostic instruments, products and services. Prior to that, she founded and served as CEO and Director of On-Q-ity, Inc., a diagnostic research company focused on improving cancer treatment through the capture of circulating tumor cells in a patient’s blood. Ms. Aspinall also spent 12 years with Genzyme Corporation, serving as President of the Genzyme Genetics division, a leading provider of esoteric and genetic tests for the reproductive, oncology and personalized medicine markets, and as President of the Genzyme Pharmaceuticals division, a custom pharmaceutical intermediates provider. Ms. Aspinall began her career as a management consultant with Bain & Company. Ms. Aspinall holds an M.B.A from Harvard Business School and a B.A. in International Relations from Tufts University.

    James Datin

    James A. Datin

    President and CEO, BioAgilytix

    James Datin became a member of the Board in August 2019 and serves on the Audit Committee and the Compensation Committee. Mr. Datin is currently President & Chief Executive Officer of BioAgilytix, a leading global bioanalytical contract research organization (CRO) that supports the development of novel therapeutic biologics. Prior to BioAgilytix, Mr. Datin was EVP and Managing Director at Safeguard Scientifics, Inc. (NYSE: SFE), a company focused on providing capital and advice to technology-driven businesses in healthcare, financial services and digital media. Mr. Datin has also served as CEO of Touchpoint Solutions, a software solutions provider; Group President of Dendrite International; Group Director, Corporate Business Strategy and Planning at GlaxoSmithKline; CEO of publicly traded Isuta Holdings Berhad; and Director, International Business at Baxter/Merck KGaA. Mr. Datin previously served on the Boards of Directors of Clarient (NASDAQ: CLRT), NuPathe Inc. (NASDAQ: PATH), the University City Science Center (Philadelphia) and Laurate Pharma. Mr. Datin earned a B.B.A. at Marshall University, an M.B.A. at the University of New Haven and an Advanced Management Degree at The Wharton School at The University of Pennsylvania.

    Nancy J. Gagliano

    Nancy J. Gagliano, MD, MBA

    Managing Director, Granite Healthcare Advisors

    Nancy J. Gagliano, MD, MBA, became a board member in November 2021 and serves on the Nominating and Corporate Governance Committee. Dr. Gagliano has more than 35 years of experience as a senior healthcare physician executive and practicing physician in internal medicine. Dr. Gagliano most recently served as an executive leader of the National Institute of Health’s RADx Tech, Rapid Acceleration of Diagnostics program. In this position she has helped oversee over one billion dollars of sponsored programs to bring millions of new COVID-19 tests to market. Prior to her work for the National Institute of Health, Dr. Gagliano was the Chief Medical Officer of Culbert Healthcare Solutions, providing strategic guidance on healthcare consulting services. Before joining Culbert Healthcare, Dr. Gagliano spent six years with CVS Health holding senior leadership positions including as the Chief Medical Officer of Minute Clinic, and as a Senior Vice President overseeing key programs such as the enterprise smoking cessation program and the development of the company’s telemedicine program. Prior to her leadership roles at CVS Health, Dr. Gagliano was a practicing internal medicine physician and held numerous leadership positions at Massachusetts General Hospital and Massachusetts General Physicians Organization. Dr. Gagliano holds an M.D. from Harvard Medical School, an MBA from Northeastern University, and a Bachelor’s of Science Degree from Union College in Computer Science and Biology.

    Eamonn Hobbs

    Eamonn Hobbs

    President, Hobbs Medical Ventures

    Eamonn P. Hobbs became a member of the Board in March 2016 and serves as the Chairman of Nominating and Corporate Governance Committee and as a member of the Compensation Committee. Mr. Hobbs serves as President of Hobbs Medical Ventures, LLC, a consulting company he founded in the healthcare field. In March 2018, he co-founded ImmunSYS, Inc. a company that is developing a new immunotherapy for late stage metastatic prostate cancer, and has since served as its Chairman of the Board and CEO. From December 2016 to June 2017, Mr. Hobbs served as President and CEO of Digital Cognition Technologies, Inc., an early stage medical device company. From July 2014 to January 2016, Mr. Hobbs served as the President and Chief Executive Officer of Antares Pharma, Inc., a specialty pharmaceutical company focused on self-injection pharmaceutical products and technologies. He also served on the Antares board of directors from 2009 to 2016. From 2009 to 2013, Mr. Hobbs served as President and Chief Executive Officer, and from 2008 to 2013 was a member of the board of directors, of Delcath Systems, Inc., a specialty pharmaceutical and medical device public company specializing in cancer treatment. Prior to Delcath Systems, Inc., Mr. Hobbs served as President and Chief Executive Officer of AngioDynamics, Inc., a company he co-founded in 1988 as a division of E-Z-EM, Inc. which grew into a leading medical technology public company with a highly diverse product line. From 1988 to 2004, Mr. Hobbs also served as Executive Vice President of Business Development of E-Z-EM, Inc., a NASDAQ-traded company. Before joining AngioDynamics, Mr. Hobbs was Director of Marketing and Product Development at NAMIC; founder, President and Chief Executive Officer of Hobbs Medical, Inc.; and a Product Development Engineer at Cook Incorporated. Mr. Hobbs received a B.S. in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell). Mr. Hobbs has served on the Board of Directors of the Medical Device Manufacturers Association since 2009.

    Ronny Lancaster

    Ronny B. Lancaster

    Former Senior Vice President, Federal Government Relations, Assurant Incorporated

    Ronny B. Lancaster became a member of the Board in May 2003 and serves as the Chairman of the Compensation Committee and is a member of the Nominating and Corporate Governance Committee. From September 2005 to December 2018, Mr. Lancaster served as Senior Vice President, Federal Government Relations of Assurant, Inc., a provider of specialty insurance and insurance-related products and services. Prior to that, Mr. Lancaster served as Chief Operating Officer of the Morehouse School of Medicine, Executive Assistant to the Secretary and Principal Deputy Assistant Secretary for Planning and Evaluation at the U.S. Department of Health and Human Services, General Counsel of Hamilton Enterprises, Inc., Senior Washington Representative for Blue Cross/Blue Shield Association, and Chief of the Division of Fee-For-Service Plans at the U.S. Office of Personnel Management. Mr. Lancaster received a B.A. in Economics from the Catholic University of America, an M.B.A. from the Wharton School of the University of Pennsylvania, and a J.D. from The Georgetown University Law Center. He is admitted to the Bars of Pennsylvania and the District of Columbia.

    Lelio Marmara

    Lelio Marmora

    Former Executive Director, Unitaid

    Lelio Marmora became a member of the board in June 2020 and serves on the Audit Committee and Nominating and Corporate Governance Committee. Mr. Marmora has held substantial roles managing global health and modernization of large-scale state investments in complex political environments. He has also played senior strategic, operational and resource mobilization roles at headquarters levels in a range of international agencies. He is the former Executive Director of Unitaid in Geneva, Switzerland, from 2014 to 2020, overseeing a portfolio of $1.5 billion in 100 countries. During his tenure, Unitaid tripled its portfolio, becoming one of the leading Global Health innovation initiatives. Prior to Unitaid, Mr. Marmora was Director for Africa and the Middle East at the Global Fund to Fight AIDS, TB and Malaria, overseeing a $4 billion portfolio. He also served as head of the Fund’s Latin America and the Caribbean Department. Earlier in his career, Mr. Marmora served in various capacities at a range of international organizations, including the World Bank, the Inter- American Development Bank and the United Nations Development Program, managing modernization of the State programs. Mr. Marmora graduated from the Université Panthéon-Assas (Paris II) with a Master’s degree in International Law and Administration of International Organizations.

    Carrie Eglinton Manner

    Carrie Eglinton Manner

    President and CEO, OraSure Technologies, Inc.

    Carrie Eglinton Manner was named President and Chief Executive Officer of OraSure Technologies in June 2022 and brings more than 25 years of healthcare leadership and transformation expertise to the Company. Prior to joining OraSure, Ms. Manner was Senior Vice President, Advanced & General Diagnostics Clinical Solutions, at Quest Diagnostics. In that role, she was responsible for bringing innovative diagnostic solutions to market in the areas of women’s health, neurology, oncology, cardiovascular, metabolic, endocrinology, infectious disease, and immunology testing services, as well as drug monitoring and toxicology. She also led Quest’s pharmaceutical services, AmeriPath/Dermpath, and international businesses, as well as their molecular genetics team in pioneering next-generation sequencing innovation. Prior to Quest Diagnostics, Ms. Eglinton Manner served for 20 years in a variety of leadership roles at GE Healthcare, a division of General Electric (GE). A champion for inclusion and diversity, Ms. Eglinton Manner was co-chair for Quest’s African American Employee Business Network and GE’s Women’s Network. Ms. Manner received a B.S. degree in mechanical engineering from University of Notre Dame.

    David Shulkin

    David Shulkin, M.D.

    President and Chief Executive Officer, Shulkin Solutions, Inc.

    David J. Shulkin, M.D. joined the Board in 2020. Since 2018, he has served as President and Chief Executive Officer of Shulkin Solutions, Inc., a company that promotes innovation in healthcare and advocates for veterans and underserved populations. From 2015 through 2018, Dr. Shulkin served in various capacities at the U.S. Department of Veterans Affairs (the “VA”), including as Secretary of the VA from 2017 to 2018 and as Under Secretary for Health from 2015 to 2017. Prior to his tenure at the VA, he served in executive leadership positions at Morristown Medical Center, Beth Israel Medical Center, Temple University Hospital, Drexel University School of Medicine, Doctor Quality, Inc. and the University of Pennsylvania Health System and Hospital of the University of Pennsylvania. Dr. Shulkin received a B.A. from Hampshire College and his M.D. from the Medical College of Pennsylvania. He also completed residencies in Internal Medicine at Yale University School of Medicine and University of Pittsburgh School of Medicine, was a Fellow in General Medicine at the University of Pittsburgh School of Medicine and was a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania School of Medicine. He is certified by the American Board of Internal Medicine.

    Anne C. Whitaker

    Anne C. Whitaker

    Managing Partner, Anne Whitaker Group, LLC

    Anne C. Whitaker became a board member in November 2021 and serves on the Audit Committee. Mrs. Whitaker is a seasoned healthcare executive and director with more than 30 years of experience and a proven track record as an executive of building and leading high-performance teams. Mrs. Whitaker currently serves as Managing Partner of Anne Whitaker Group, LLC, a board and private equity advisory firm, and is the current Chairperson of the Board of Aerami Therapeutics, a private life science company. Prior to taking the Chair role at Aerami, she served as the CEO from October 2018 to November 2020 and as a director from July 2018. She also serves as an independent director on the boards of three public companies including Faron Pharmaceuticals, a development stage pharma company; Caladrius, a development stage biotech company; and Mallinckrodt, a specialty pharmaceutical company. In addition to her board work, she is an active industry advisor to private equity and venture capital funds in the U.S. and Europe. Mrs. Whitaker started her healthcare career with The Upjohn Company selling pharmaceuticals. She subsequently transitioned to GlaxoSmithKline PLC, where she spent 19 years and rose in the commercial ranks from a sales representative to become a Senior Vice President, Business Unit Head for the Cardiovascular, Metabolic, and Urology franchises in 2009. She joined Sanofi SA in 2011 as the President of the North America Pharmaceutical Region. Anne served as the CEO and President of Synta Pharmaceuticals, Inc. in 2014 and 2015. She joined Bausch Health as an Executive Vice President and Company Group Chairman for the Branded Pharmaceuticals segment in mid-2015. From February 2017 until April 2018, she served as the CEO and President of Novoclem Therapeutics, Inc. Mrs. Whitaker holds a Bachelor of Science degree in chemistry from the University of North Alabama.